Mycophenolate Mofetil Appears Effective for the Treatment of Patients With Refractory Crohn's Disease.

ABSTRACT:

Background

Medically refractory Crohn's disease (CD) is associated with a high risk of complications. Mycophenolate mofetil (MMF), a small molecule immunosuppressant, has limited data in patients with CD, and objective endoscopic response to MMF has not been reported.

Aims

We evaluated the safety and clinical, endoscopic, and biochemical effectiveness of off-label MMF for refractory CD as monotherapy or in combination with a biologic in patients with CD.

Methods

We retrospectively assessed adverse events (AEs), clinical response (Harvey-Bradshaw index), endoscopic response (simple endoscopic score in Crohn's disease), and physician global assessment at an academic medical center and county hospital.

Results

60 patients received MMF as monotherapy (n = 40

SUBMITTER: Rosenfeld S 

PROVIDER: S-EPMC11655623 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature